Prio Wealth Limited Partnership Trims Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Prio Wealth Limited Partnership trimmed its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 42.4% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 515 shares of the medical equipment provider’s stock after selling 379 shares during the period. Prio Wealth Limited Partnership’s holdings in Intuitive Surgical were worth $229,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ISRG. One Wealth Management Investment & Advisory Services LLC grew its stake in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after buying an additional 23 shares in the last quarter. Indiana Trust & Investment Management CO grew its position in Intuitive Surgical by 5.3% in the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares in the last quarter. Hoxton Planning & Management LLC increased its stake in Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 25 shares during the period. First Affirmative Financial Network lifted its position in shares of Intuitive Surgical by 2.7% during the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after purchasing an additional 26 shares in the last quarter. Finally, Moors & Cabot Inc. boosted its stake in shares of Intuitive Surgical by 2.3% in the second quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock valued at $516,000 after purchasing an additional 26 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ISRG. Evercore ISI increased their target price on shares of Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a report on Tuesday. Piper Sandler increased their price objective on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Robert W. Baird boosted their target price on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Stifel Nicolaus increased their price target on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Finally, BTIG Research boosted their price objective on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical has a consensus rating of “Moderate Buy” and a consensus price target of $449.70.

Insider Buying and Selling at Intuitive Surgical

In other news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark Brosius sold 2,115 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the sale, the insider now directly owns 295 shares of the company’s stock, valued at $145,113.45. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Stock Up 0.4 %

Shares of NASDAQ ISRG opened at $486.62 on Thursday. The business has a 50-day moving average price of $474.88 and a 200 day moving average price of $430.58. The stock has a market cap of $172.60 billion, a PE ratio of 87.84, a price-to-earnings-growth ratio of 5.39 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.18 earnings per share. Sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.